Speaker illustration

Doctor Hardean Achneck

Haemonetics Corporation, Braintree (United States of America)

Novel thromboelastography point-of-care test detects all commercially available DOACs at therapeutic concentrations and classifies them as direct thrombin or factor Xa inhibitors with high consistency

Event: ESC Congress 2018

Topic: Anticoagulants

Session: Bleeding risk and oral anticoagulation

Thumbnail

ESC 365 is supported by